HD Insights: Volume 7

HD Insights: Volume 7

HD Insights Volume 7 (PDF)

February 23rd, 2014 Heather Hare

Meet the Investigator

January 1st, 2014 rtullio VITAL SIGNS NAME: Kathleen (Kitty) Clarence-Smith, MD, PhD CURRENT POSITION: Chairman of the Board of Chase Pharmaceuticals; Partner, KM Pharmaceuticals Consulting (clients include Lundbeck). EDUCATION: MD and PhD in Neurosciences, Université de Tours, France; Residency in Neurology, Salpêtrière, Paris, France; post-doctoral fellowship at Johns Hopkins University School of Medicine, Department of Pharmacology and Experimental Therapeutics.
+ Read More

PREDICTions: Using High-Performance Computing to Visualize the HD Brain

January 1st, 2014 rtullio By: Hans Johnson, PhD For more than a decade, the PREDICT-HD study has followed approximately 1,400 individuals around the world, including both premanifest carriers of the mutant Huntingtin allele and normal control individuals, in an attempt to identify the earliest signs of HD. PREDICT investigators at 28 sites obtain yearly MRI scans and cognitive, behavioral,
+ Read More

Meet the CEO

January 1st, 2014 rtullio VITAL SIGNS NAME: Pratik Shah, PhD, MBA CURRENT POSITION: President, Chief Executive Officer, and Director of Auspex Pharmaceuticals EDUCATION: PhD in Biochemistry and Molecular Biology and MBA, University of Chicago. HOBBIES: Spending time with family, traveling the west coast, and reading; recently finished Michael Lewis’ Boomerang. Dr. Shah strives to integrate his training in the
+ Read More

Editor’s Letter

January 1st, 2014 rtullio Welcome to the latest edition of HD Insights, released at the 9th Annual CHDI Huntington’s Disease Therapeutics Conference. HD Insights brings you the latest in HD research, and we are grateful to the HSG, our sponsors, and our more than 1500 subscribers for their continuing support of this mission. Throughout this issue, we explore the
+ Read More

Research Round-Up

January 1st, 2014 rtullio By: Lise Munsie, PhD In cell biology… The exact molecular mechanism of the huntingtin (Htt) protein is largely unknown. A paper from Dr. Solomon Snyder’s lab at Johns Hopkins that probes the link between Htt and the striatal-specific protein Rhes was recently published in the Journal of Biological Chemistry.1 This paper implicates Rhes in mTOR-independent
+ Read More

Prana Releases Promising Results

January 1st, 2014 rtullio Prana Biotechnology released promising results from its phase 2 study of PBT2 in individuals with mild to moderate Huntington disease. In a randomized, double-blind, placebo-controlled study, 104 (95%) of 109 study participants completed the 26-week study on one of the three study arms – PBT2 250mg daily, PBT2 100mg daily, or placebo. Serious adverse events
+ Read More

Meet the Company

January 1st, 2014 rtullio VITAL SIGNS NAME: Auspex Pharmaceuticals HEADQUARTERS: La Jolla, CA STOCK PRICE AS OF 2/13/2014: $22.20 MARKET CAPITALIZATION: $478 M EMPLOYEES: about 20 Pratik Shah, PhD, MBA, is the President, Chief Executive Officer, and Director of Auspex Pharmaceuticals. He came to Auspex in 2007 as an investor, and has since led the company as Chairman or
+ Read More

HD Research around the World: Canada

January 1st, 2014 rtullio By: Lise Munsie, PhD Investigators across Canada are heavily involved in HD research; these teams tackle a broad array of HD related research topics ranging from basic cell biology and biochemistry of the huntingtin (Htt) protein, to therapeutic leads and large clinical trials. On the east coast, Dr. Eileen Denovan-Wright’s lab at the University of
+ Read More

Meet the Compound: SD-809 (dutetrabenazine)

January 1st, 2014 rtullio Molecular Formula: C19H21D6NO Molecular Weight: 324 g/mol Mechanism of Action: Tetrabenazine reversibly inhibits monoamine re-uptake, which depletes monoamines and reduces involuntary movements.1 Auspex Pharmaceuticals, developer of SD-809, has shown that deuteration of tetrabenazine may slow its metabolism and decrease the need for large repeated doses.2,3 A Brief History of Deuterated Pharmaceuticals By: Meredith Achey, BM
+ Read More

Highlights from the Huntington Study Group 2013 Annual Meeting and Clinical Research Symposium

January 1st, 2014 rtullio By: Christina Vaughan, MD, MHS For twenty years, the Huntington Study Group (HSG) has hosted an internationally recognized forum for training and educating HD researchers, combined with programs for families living with HD and other community members. HSG 2013 opened with the HSG Annual Meeting, including training courses open to all attendees, and the Local
+ Read More
  • HD Insights

    Our mission is to promote, disseminate, and facilitate research in Huntington disease. To fulfill this mission, we are guided by an outstanding Editorial Board that includes representatives from three continents, academia, industry, and the HD community.

    Subscribe to HD Insights

    HD Insights Archives

    Vol. 17, Spring 2017
    Vol. 16, Winter 2017
    Vol. 15, Fall 2016
    Vol. 14, Spring 2016
    Vol. 13, Winter 2016
    Vol. 12, Fall 2015
    Vol. 11, Spring 2015
    Vol. 10, Winter 2015
    Vol. 9, Winter 2014
    Vol. 8, Fall 2014
    Vol. 7, Winter 2014
    Vol. 6, Winter 2013
    Vol. 5, Fall 2013
    Vol. 4, Spring 2013
    Vol. 3, Fall 2012
    Vol. 2, Winter 2012
    Vol. 1, Fall 2011